Volume 101, Issue 12 pp. 4653-4659
Research Article

Interaction of n-acetylcysteine and cysteine in human plasma

Kendra K. Radtke

Kendra K. Radtke

Center for Orphan Drug Research, Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota 55455

Search for more papers by this author
Lisa D. Coles

Corresponding Author

Lisa D. Coles

Center for Orphan Drug Research, Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota 55455

Center for Orphan Drug Research, Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota 55455. Telephone: +612-624-1861; Fax: +612-626-9985Search for more papers by this author
Usha Mishra

Usha Mishra

Center for Orphan Drug Research, Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota 55455

Search for more papers by this author
Paul J. Orchard

Paul J. Orchard

Division of Pediatric Hematology-Oncology, Blood and Marrow Transplantation, Department of Pediatrics, University of Minnesota, Minneapolis, Minnesota 55455

Search for more papers by this author
Mary Holmay

Mary Holmay

Center for Orphan Drug Research, Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota 55455

Search for more papers by this author
James C. Cloyd

James C. Cloyd

Center for Orphan Drug Research, Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota 55455

Search for more papers by this author
First published: 27 September 2012
Citations: 4

Abstract

N-acetyl-l-cysteine (NAC), a well-known antioxidant, has been successfully used as adjuvant therapy for late-stage childhood cerebral adrenoleukodystrophy (c-ALD); however, the mechanisms of NAC action are poorly understood. Previous research indicates that NAC serves as a precursor to l-cysteine (Cys), the rate-limiting substrate in the biosynthesis of glutathione (GSH), a potent, endogenous antioxidant. We hypothesized that NAC acts by liberating protein-bound Cys in plasma in an NAC concentration-dependent manner, which increases unbound Cys available for GSH biosynthesis. Human plasma was incubated for 1 h with varying, clinically relevant concentrations of NAC (0–1000 µg/mL). The effect of this interaction over time was evaluated by incubating plasma for 5–90 min with 100 µg/mL NAC. Unbound and bound Cys and NAC were separated by ultrafiltration, and concentrations were measured using high-performance liquid chromatography–mass spectrometry. Significant increases in unbound Cys were observed with increasing NAC concentrations. Also, Cys plasma protein binding decreased from 85% (10 µg/mL NAC) to approximately 0% (1000 µg/mL). Total endogenous Cys was 66% unbound at 5 min after incubation. These results demonstrate that NAC liberates endogenous, protein-bound Cys in human plasma at clinically relevant NAC concentrations. A greater understanding of NAC actions will aid in the optimization of NAC therapy including its use in c-ALD. © 2012 Wiley Periodicals, Inc. and the American Pharmacists Association J Pharm Sci 101:4653–4659, 2012

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.